You are here

Phase II Trial of BCX-1777 in T-Cell Leukemia Patients Initiated

BIRMINGHAM, Ala., March 31 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. announced today that the first patient has been dosed in its Phase IIa trial of BCX-1777, the Company's purine nucleoside phosphorylase (PNP) inhibitor that is currently in clinical development for treatment of T-cell cancers. The small-molecule drug, which causes biochemical changes that result in blocking of the T-cell's DNA synthesis machinery, recently received orphan drug designation from the U.S. Food and Drug Administration for treatment of T-cell non-Hodgkin's lymphoma.

The Phase II clinical trial is a multicenter, global, open-label study to determine the efficacy of long-term dosing with BCX-1777. The trial will be divided into two parts, Phase IIa and IIb. The Phase IIa study will evaluate response rate and duration of response in 20 patients with refractory T-cell leukemia who have failed 2 previous treatments. The six-week dosing regimen will consist of consecutive seven-day cycles. Patients will receive a once- daily infusion of the drug at 40 mg/m2 for five days, followed by a two-day rest period. If indicated, the dose may be increased to 90mg/m2 after two cycles. The primary endpoint will be leukemic cell counts in both the peripheral blood and the bone marrow. BioCryst anticipates results from Phase IIa to be available during 2004. Assuming the clinical data from the first part of the trial is sufficiently positive, BioCryst expects to initiate a larger Phase IIb study of up to 100 patients. The company intends to seek Special Protocol Assessment from the FDA for the Phase IIb trial.

"We are pleased to have made such substantial progress with BCX-1777 in such a short time, and this is a very exciting milestone for us," said Dr. Charles Bugg, Chairman and Chief Executive Officer of BioCryst. "The data we have seen to date indicates that BCX-1777 is well tolerated by patients and has the potential to dramatically lower leukemic cell counts and prevent T-cell proliferation without cytotoxic effect on other cell functions. We are anxious to move this product candidate forward as quickly as possible, in order to reach cancer patients who have exhausted other treatment options for this rare but deadly form of the disease."

About T-Cell Cancers

The human immune system employs specialized cells, including T-cells, to control infection by recognizing and attacking disease-causing viruses, bacteria and parasites. T-cells are an essential part of the body's immune system that serve a dual purpose to both orchestrate and participate in the body's immune response. For the most part, this system works flawlessly to protect the body. However, when T-cells multiply uncontrollably, T-cell proliferative diseases, including T-cell cancers, occur. The most common form of leukemia in children is acute lymphoblastic leukemia (also known as ALL). According to the American Cancer Society, 3,830 new cases (adult and children combined) will be diagnosed in the United States in 2004.

Source: BioCryst Pharmaceuticals, Inc.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time